Expression of Prostate-specific membrane antigen in transitional cell carcinoma of the bladder: Prognostic value?

Jean Luc Gala, Sylvain Loric, Yves Guiot, Samuel Ray Denmeade, Alyssa Gady, Francis Brasseur, Michel Heusterspreute, Pascal Eschwege, Philippe De Nayer, Paul Van Cangh, Bertrand Tombal

Research output: Contribution to journalArticlepeer-review

Abstract

The expression of Prostate-specific membrane antigen (PSMA) mRNA was assessed in the normal bladder urothelium (n = 9), transitional cell carcinoma (TCC) specimens (n = 52), TCC-derived cell lines (n = 3), and preoperative blood samples from TCC patients (n = 27), Specific PSMA mRNA was found in 100% of normal and malignant tissues and two cell lines. PSMA protein was detected in normal (n = 3) and malignant tissues (n = 4). Using a PSMA-specific substrate, PSMA enzymatic activity was found in two bladder cell lines and correlated with immunostaining. Seven of the 27 TCC preoperative blood samples were positive by reverse transcription-PCR. These preliminary results, obtained on a nonrandomized cohort of patients, correlated with tumor invasion (positive RT-PCR: 0% for pT ≤2 versus 4.1% for pT ≥3) and 2-year survival rate (81% in the PSMA-negative group versus 29% in the PSMA-positive group). Although the clinical usefulness of this assay requires confirmation in larger prospective randomized trials, current preliminary results suggest that a blood-borne PSMA mRNA PCR assay may be a useful tool to predict a poor outcome in TCC patients.

Original languageEnglish (US)
Pages (from-to)4049-4054
Number of pages6
JournalClinical Cancer Research
Volume6
Issue number10
StatePublished - Jan 1 2000

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Expression of Prostate-specific membrane antigen in transitional cell carcinoma of the bladder: Prognostic value?'. Together they form a unique fingerprint.

Cite this